ReviewEULAR rheumatology open2026
Arrhythmic risk in axial spondyloarthritis: a narrative review.
Review in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Axial spondyloarthritis (axSpA) is a chronic systemic inflammatory disorder affecting the axial skeleton and potentially the peripheral joints as well as extraskeletal tissues. Chronic systemic inflammation is also known to play a major role in the pathogenesis of conduction disturbances and arrhythmias, through chronic fibrotic scarring and cytokine-mediated delay of atrioventricular (AV) conduction as well as atrial remodelling. More specifically, the prevalence of AV block appears to be high, resulting in an increased risk for pacemaker implantation. Furthermore, axSpA is associated with an increased prevalence of atrial fibrillation, even when adjusting for other cardiovascular risk predictors. As the development of arrhythmia in axSpA appears to be associated with disease activity, controlling the systemic inflammation could potentially offer a viable addition to conventional antiarrhythmic treatment. However, the possible proarrhythmic effects of conventional and newer anti-inflammatory drugs in patients with axSpA need to be further elucidated in the future.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.